Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G, Offidani A, Ferrucci SM, Amoruso GF, Rossi M, Stingeni L, Malara G, Grieco T, Foti C, Gattoni M, Loi C, Iannone M, Talamonti M, Stinco G, Rongioletti F, Pigatto PD, Cristaudo A, Nettis E, Corazza M, Guarneri F, Amerio P, Esposito M, Belloni Fortina A, Potenza C, Fabbrocini G; DADE - Dupilumab for Atopic Dermatitis of the Elderly study group. Patruno C, et al. Among authors: ferrucci sm. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):958-964. doi: 10.1111/jdv.17094. Epub 2021 Jan 19. J Eur Acad Dermatol Venereol. 2021. PMID: 33332697
Serum heavy metals and childhood skin diseases.
Pigatto PD, Brambilla L, Ferrucci S, Guzzi G. Pigatto PD, et al. Pediatr Allergy Immunol. 2011 May;22(3):342; author reply 343. doi: 10.1111/j.1399-3038.2010.01107.x. Pediatr Allergy Immunol. 2011. PMID: 21457337 No abstract available.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G, Diani M, Conic RRZ, Colli L, Ferrucci S, Martina E, Offidani AM, Pigatto PDM. Damiani G, et al. Int Arch Allergy Immunol. 2019;178(1):45-49. doi: 10.1159/000492532. Epub 2018 Nov 5. Int Arch Allergy Immunol. 2019. PMID: 30396176
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N, Ferrucci S, Pepe P, Liberati S, Pigatto PD, Offidani A, Martina E, Girolomoni G, Rovaris M, Foti C, Stingeni L, Cristaudo A, Canonica GW, Nettis E, Asero R. Marzano AV, et al. J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924. doi: 10.1111/jdv.15350. Epub 2018 Dec 7. J Eur Acad Dermatol Venereol. 2019. PMID: 30451325 Free article.
163 results